CMS rule cuts reimbursement for new Part B drugs

Under a new rule, CMS will reimburse newly launched physician-administered drugs covered under Medicare Part B at the wholesale acquisition cost (WAC) plus 3%, down from WAC plus 6%, effective Jan. 1, 2019.

Under the current Part B buy-and-bill model, CMS reimburses doctors or hospitals for the

Read the full 467 word article

User Sign In